Evidence map›Paper›PMID 31855154›Full record

ArticleBlood transfusion = Trasfusione del sangue2020

Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.

Ugo Salvadori, Fabio Vittadello, Ahmad Al-Khaffaf, Armin Maier, Paola C Cappelletto, Massimo Daves, Bernd Raffeiner

Registry-linked trialOpen access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07523646 (Anemia Therapy in Patients With Infective Endocarditis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07523646 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Anemia Therapy in Patients With Infective Endocarditis (POET-IRON)

TypeinterventionalSponsorRigshospitalet, DenmarkRan2026 to 2028Enrolled74ConditionsInfective Endocarditis (IE), Severe AnemiaArmsAdjunctive anemia therapy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ugo SalvadoriDepartment of Immunohaematology and Transfusion, Central Hospital of Bolzano, Bolzano, Italy.
Fabio VittadelloExplora - Research and Statistical Analysis, Padova, Italy.
Ahmad Al-KhaffafDepartment of Immunohaematology and Transfusion, Central Hospital of Bolzano, Bolzano, Italy.
Armin MaierRheumatology Unit, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy.
Paola C CappellettoHospital Pharmacy, Central Hospital of Bolzano, Bolzano, Italy.
Massimo DavesDepartment of Immunohaematology and Transfusion, Central Hospital of Bolzano, Bolzano, Italy.
Bernd RaffeinerRheumatology Unit, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy.
Ospedale di Bolzano · ITExplora (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to evaluate the efficacy and safety of ferric carboxymaltose in rheumatic patients with iron deficiency anaemia. MATERIALS AND

methodsThe study retrospectively evaluated a cohort of 34 patients with iron deficiency anaemia affected by inflammatory rheumatic diseases that are refractory or intolerant to oral iron therapy. They were treated with ferric carboxymaltose for a total of 56 cycles of treatment. The primary end point was to evaluate the increase of haemoglobin after ferric carboxymaltose treatment. The secondary end point was safety, including the occurrence of disease flare.

resultsMedian age of the cohort was 60 years (range 31-91 years), with a male/female ratio of 4/30. Nine (26.5%) were affected by rheumatoid arthritis, 10 (29.4%) by spondyloarthritis, and 15 (44.1%) by other autoimmune connective tissue diseases. Median time from diagnosis was 7 years (IQR 2-12). At time of treatment (T DISCUSSION: In patients affected by inflammatory rheumatic diseases, ferric carboxymaltose is safe and effective in correcting iron deficiency anaemia.

Indexed as

Administration, IntravenousAdultAgedAged, 80 and overAnemia, Iron-DeficiencyFemaleFerric CompoundsHumansMaleMaltoseMiddle AgedRetrospective StudiesRheumatic Diseasesferric carboxymaltoseFerric CompoundsMaltose

Identifiers

PMID31855154
PMCPMC7250685
OpenAlexW2995391484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.